Clinical trial · no report yet · Phase 2
IFM 2022-01
Minimal Residual Disease-based Strategy With T-Cell Redirector After Treatment With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple Myeloma
- NCT06353022 ↗
- Active, not recruiting
- Nantes University Hospital
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 4 | |
| YouTube | 1 |
The trial
ClinicalTrials.gov- Official title
- Minimal Residual Disease-based Strategy With T-Cell Redirector After Treatment With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple Myeloma: A Phase 2 (IFM 2022-01)
- Phase
- Phase 2
- Status
- Active, not recruiting
- Conditions
- Multiple Myeloma
- Interventions
- Teclistamab; Talquetamab; Lenalidomide; Bortezomib; Daratumumab; Dexamethasone
- Arms
- Teclistamab and Lenalidomide · Experimental
- Talquetamab andTeclistamab · Experimental
- Enrollment
- 103 (estimated)
- Primary outcomes
- Rate of sustained MRD negativity (NGS, 10^-5)
- Rate of conversion from positive MRD to negative MRD (NGS, 10^-5)
- Sponsor
- Nantes University Hospital with Janssen Pharmaceutica
- Start
- Jun 26, 2024
- Primary completion
- Apr 26, 2028 (estimated)
- Results posted
- No
- Registry record
- NCT06353022 · updated Mar 17, 2026